Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Ipilimumab

4

XII.d Myocarditis (can be fulminant)

1
Last update : 20/10/2014
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist
See also under
CTLA4 blocking immunotherapy
3
Immune checkpoint inhibitors (ICI) - ICI combinatorial Rx
5
Tremelimumab
1

Publications

Immune-related fulminant myocarditis in a patient receiving ipilimumab therapy for relapsed chronic myelomonocytic leukaemia.
European journal of heart failure 2017 May;19;682-685 2017 May
Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab.
Oncoimmunology 2017;6;e1361097 2017
Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management.
Scientifica 2013;2013;857519 2013

Powered by

  • ^
  • Contact
  • Cookies
  • About